Revvity Reports Mixed Q3 Results, Raises Profit Outlook

Revvity, Inc. (NYSE: RVTY) has announced its financial results for the third quarter of 2025, revealing a mix of achievements and challenges. The company reported revenue of $699 million, reflecting modest year-over-year growth, while adjusted earnings per share surpassed expectations. Management reaffirmed its organic growth targets and raised full-year EPS guidance, signaling confidence in Revvity’s long-term strategy.

Earnings Beat Despite Soft Revenue Reflects Efficient Execution

Revvity, Inc. reported a revenue of $699 million for the third quarter of 2025, showing a 2% growth from the same period last year. Despite this increase, the revenue fell slightly short of the expected $699.98 million. The company’s GAAP earnings per share (EPS) stood at $0.40, a decrease from $0.77 in the previous year, but the adjusted EPS from continuing operations was $1.18, surpassing the anticipated $1.14. This adjusted EPS indicates a stronger operational performance than initially forecasted.

When comparing the current quarter’s performance against expectations, Revvity demonstrated resilience in its adjusted earnings, even though the overall revenue did not meet projections. The adjusted operating income for the quarter was reported at $182 million, down from $193 million in the same period last year, with an adjusted operating profit margin of 26.1%. This figure, although lower than the previous year’s 28.3%, reflects the company’s efforts to maintain profitability amid various market challenges.

The Life Sciences segment reported a revenue of $343 million, a slight increase from $339 million last year, while the Diagnostics segment recorded a revenue of $356 million, up from $345 million. The Diagnostics segment showed a 3% revenue growth, with 2% organic growth, indicating a positive trend in this area. However, both segments experienced a decrease in adjusted operating income and profit margins compared to the previous year, highlighting areas for potential improvement.

Join our Telegram group and never miss a breaking digital asset story.

Revvity Reaffirms Revenue Goals, Raises EPS Expectations

Looking forward, Revvity has updated its full-year revenue guidance to a range of $2.83 billion to $2.88 billion, adjusting for recent changes in foreign currency exchange rates. The company has reaffirmed its organic growth guidance of 2% to 4%, indicating confidence in its ongoing business strategies and market position. Furthermore, Revvity has raised its adjusted EPS guidance for the full year to between $4.90 and $5.00, reflecting a positive outlook on its ability to deliver strong financial results.

The company’s strategic initiatives, including key innovations and partnerships, are expected to play a significant role in driving future growth. Revvity’s management has expressed optimism about the company’s trajectory, highlighting the potential for continued success in 2026 and beyond. The introduction of a new $1 billion share repurchase program also signals confidence in the company’s financial health and commitment to returning value to shareholders.

Revvity’s guidance reflects a balanced approach to navigating market dynamics while focusing on long-term growth opportunities. The company’s emphasis on innovation and strategic execution is poised to enhance its competitive position and support its financial objectives. As Revvity continues to leverage its expertise in health science solutions, it remains well-positioned to achieve its growth targets and deliver value to its stakeholders.

Disclaimer: The author does not hold or have a position in any securities discussed in the article. All stock prices were quoted at the time of writing.